ArticleBiology direct2026
Dapagliflozin induces renal lipidomic remodeling and systemic metabolic improvement.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDiabetic nephropathy (DN) is a leading cause of end-stage renal disease worldwide. Sodium-glucose cotransporter-2 inhibitors (SGLT2is), such as dapagliflozin, have demonstrated renoprotective effects in the treatment of DN. In addition to kidney protection, SGLT2is confer significant cardiovascular and hepatic benefits; however, the mechanisms underlying these multi-organ protective effects have not yet been fully elucidated.
methodsA total of 51 patients with newly diagnosed DN were enrolled and received dapagliflozin treatment (10 mg/day; AstraZeneca) for 12 weeks. Circulating lipid profiles were analyzed using untargeted lipidomics. To further characterize renal lipid alterations, spatial metabolomics was performed on kidney tissues obtained from dapagliflozin-treated db/db mice.
resultsDapagliflozin treatment significantly reduced serum triglyceride levels while increasing high-density lipoprotein cholesterol in DN patients. Untargeted lipidomic analysis revealed extensive remodeling of the circulating lipidome, marked by reductions in pro-fibrotic and pro-inflammatory lipid species and concurrent increases in renoprotective lipids, including fatty acid esters of hydroxy fatty acids. Machine-learning analyses identified specific lipid ratio changes that were positively correlated with renal function parameters, notably ratios involving SM(d14:0/30:1) and PC(16:0e/18:2). Furthermore, spatial metabolomic profiling in db/db mice demonstrated that dapagliflozin alleviated renal lipotoxicity by reducing the accumulation of toxic lipid species and promoting lipid redistribution predominantly within the renal cortex. Mechanistically, dapagliflozin treatment was associated with enhanced renal fatty acid β-oxidation and sphingolipid degradation while suppressing key anabolic pathways, including de novo lipogenesis and glycerophospholipid and sphingolipid biosynthesis. These metabolic alterations were further evidenced by altered expression of key regulatory enzymes.
conclusionDapagliflozin is associated with remodeling of renal lipid metabolism in DN, accompanied by improvements in systemic lipid profile. The improvement in circulating dyslipidemia may partially explain the cardiovascular and hepatic protective effects associated with dapagliflozin therapy. Collectively, these findings provide mechanistic insight into the lipid-mediated, multi-organ benefits of dapagliflozin in DN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.